The infertility treatment Recobell is available in general hospitals. According to related industries, Ferring Pharmaceutical's Recobell passed the Drug Committee of medical institutions with infertility centers such as Sinchon Severance Hospital, Bundang Seoul National University Hospital, and Bundang Cha Hospital. Along with the expansion of insurance benefit standards in May, the benefit is also expanding. Originally, the drug, which was only administered alone, is covered by Controlled Ovarian Stimulation to mature a number of oocytes in women undergoing auxiliary reproduction such as IVF or ICSI with hMG combination therapy. The expansion of Recobell's benefit criteria was based on the MARCS study, a multi-agency